Humacyte Inc. (HUMA)
NASDAQ: HUMAHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
HUMA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $131.20M
- EPS (TTM)
- -$0.51
- Dividend yield
- None
- 52-week range
- 0.46 – 1.90
- Day range
- 0.46 – 0.4799
- Volume / Avg
- 3.91M / 6.35M
- Beta
- —
- Shares outstanding
- 277.80M
52-week range
HUMA stock today
Humacyte (HUMA) closed at $0.4723 on Oct 7, down 1.19% (-$0.0057), versus the S&P 500's 0.22% decline. Shares are 75.1% below their 52-week high of $1.90 and 2.7% above the 52-week low of $0.46, near the bottom of the past year's range. HUMA is down 50.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 71.3%.
Humacyte has posted a net loss over the last twelve months (EPS of -$0.51), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Humacyte
Company profileHumacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Laura E. Niklason M.D., Ph.D.
- Headquarters
- Durham, NC
- Employees
- 184
- IPO year
- 2020
- Website
- humacyte.com
Analyst forecast
ForecastConsensus (6 analysts)
buy
Avg. price target
$1.63+245.12%
- Strong buy 1
- Buy 3
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
HUMA news
All HUMA newsHumacyte peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CLLSCellectis S.A. ADR | 1.34 | -4.29% | $134.96M | vs HUMA |
| RNAAtrium Therapeutics Inc. | 7.93 | -0.75% | $135.65M | vs HUMA |
| TNXPTonix Pharmaceuticals Holding Corp. | 7.55 | -1.88% | $129.49M | vs HUMA |
| SPRBSpruce Biosciences Inc. | 44.40 | +3.77% | $127.61M | vs HUMA |
| HURATuHURA Biosciences Inc. | 1.98 | +1.54% | $126.18M | vs HUMA |
| TLSATiziana Life Sciences Ltd. | 1.10 | -0.90% | $139.99M | vs HUMA |
| NRXPNRX Pharmaceuticals Inc. | 2.90 | -1.36% | $125.56M | vs HUMA |
| FHTXFoghorn Therapeutics Inc. | 2.09 | +6.09% | $124.12M | vs HUMA |
Indexes, lists and sector
Appears in lists
Humacyte stock FAQ
What is Humacyte's stock price today?
HUMA last traded at $0.4723 as of Oct 7, 4:00 PM EDT, down 1.19% on the day. Prices are delayed at least 15 minutes.
Who is Humacyte's CEO?
Dr. Laura E. Niklason M.D., Ph.D. is the chief executive officer of Humacyte Inc., which has about 184 employees.
What is the HUMA 52-week high?
The 52-week high for HUMA is $1.90 and the 52-week low is $0.46. The stock is currently 75.1% below its high.